Incyte Corporation
- 取引所
- 米国株
- 国 / 地域
- USA
- 上場日
- 1993年11月4日
- 従業員数
- 2,844
- 公式サイト
- www.incyte.com
総合バリュエーションレンジ · 保守的 $80–$88 / 妥当 $97–$107 / 楽観的 $122–$141。$118.87 時点で 妥当レンジと楽観的レンジの間。
レポート公開時 $97.34（2026年5月28日）
データ提供：EODHD、報告通貨で表示。参考情報であり、投資助言ではありません。
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
沿革
Incyte Corporation was incorporated in 1991 in Delaware and completed its IPO on November 4, 1993, initially listing on the American Stock Exchange and later moving to Nasdaq. In its early years the company concentrated almost entirely on information and genomics products such as databases and information services. As demand for research tools weakened and genomic information became increasingly public, Incyte began drug discovery and development in early 2002, renamed itself from Incyte Genomics Inc to Incyte Corporation in March 2003, and in 2004 closed its Palo Alto information-products business, recognizing a $42.1 million restructuring charge to focus on small-molecule drug development. In 2009 it signed an ex-US ruxolitinib collaboration with Novartis and a baricitinib license and development agreement with Lilly. A pivotal milestone came in November 2011 when the FDA approved Jakafi for myelofibrosis, which the company described as the first FDA-approved therapy for the disease. In April 2018 the phase 3 ECHO-301/KEYNOTE-252 trial of epacadostat combined with Keytruda failed and was halted. The company later expanded its portfolio with the 2020 launches of Pemazyre and Monjuvi, the 2021 US approval of Opzelura for atopic dermatitis, and in 2024 the FDA approval of Niktimvo, the acquisition of global exclusive rights to tafasitamab, the acquisition of Escient for $750 million, and an approximately $2 billion Dutch-auction tender repurchase at $60 per share covering 33.326 million shares. In June 2025 Bill Meury succeeded Herve Hoppenot as CEO. Total revenue grew from $1.54 billion in 2017 to $2.67 billion in 2020, $2.891 billion in 2021, $3.4 billion in 2022, $3.7 billion in 2023, $4.2 billion in 2024, and $5.14 billion in 2025. The company is headquartered in Wilmington, Delaware and had 2,844 employees.
業界での地位
Incyte is a commercial-stage mid-cap biopharmaceutical company reported as a single operating segment, operating across the United States, Europe, Canada, and Japan, and selling through specialty and retail pharmacies, hospital pharmacies, and distributors. Its commercial engine has three layers: US self-marketed product sales centered on Jakafi; the dermatology franchise built on Opzelura; and a hematology-oncology portfolio that includes Iclusig, Pemazyre, Monjuvi/Minjuvi, Niktimvo, and Zynyz; in addition it earns ex-US royalties on products such as Jakavi, Olumiant, and Tabrecta. In 2025 net product revenue was $4.35 billion, of which Jakafi contributed about 71%, Opzelura about 16%, and the remaining hematology-oncology products about 13%. The company has collaboration and license agreements with Novartis, Lilly, and Syndax, and at the end of 2025 Novartis and Lilly together accounted for 17% of accounts receivable. Companies cited as capital-markets comparables are Exelixis (2025 revenue $2.32 billion, with the cabozantinib franchise about 92% of revenue), Neurocrine Biosciences (2025 revenue $2.83 billion, with Ingrezza about 89% of revenue), and Jazz Pharmaceuticals (2025 revenue $4.3 billion, with Xywav at $1.7 billion and Epidiolex at $1.1 billion). Baker Bros.-related entities held roughly 15.4% to 15.6% of the company, with board chairman Julian Baker representing that holding.
この銘柄のレポートはお使いの言語でまだありません。